CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma | Zendy

Ranjana H. Advani | Zendy; Ian W. Flinn | Zendy; Leslie Popplewell | Zendy; Andres Forero | Zendy; Nancy L. Bartlett | Zendy; Nilanjan Ghosh | Zendy; Justin Kline | Zendy; Mark Roschewski | Zendy; Ann S. LaCasce | Zendy; Graham P. Collins | Zendy; Thu Ha Tran | Zendy; Judith Lynn | Zendy; James Y. Chen | Zendy; Jens-Peter Volkmer | Zendy; Balaji Agoram | Zendy; Jie Huang | Zendy; Ravindra Majeti | Zendy; Irving L. Weissman | Zendy; Chris H. Takimoto | Zendy; Mark P. Chao | Zendy; Sonali M. Smith | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma

Author(s) -

Ranjana H. Advani,

Ian W. Flinn,

Leslie Popplewell,

Andres Forero,

Nancy L. Bartlett,

Nilanjan Ghosh,

Justin Kline,

Mark Roschewski,

Ann S. LaCasce,

Graham P. Collins,

Thu Ha Tran,

Judith Lynn,

James Y. Chen,

Jens-Peter Volkmer,

Balaji Agoram,

Jie Huang,

Ravindra Majeti,

Irving L. Weissman,

Chris H. Takimoto,

Mark P. Chao,

Sonali M. Smith

Publication year - 2018

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1807315

Subject(s) - rituximab , blockade , medicine , lymphoma , hodgkin lymphoma , oncology , receptor

The Hu5F9-G4 (hereafter, 5F9) antibody is a macrophage immune checkpoint inhibitor blocking CD47 that induces tumor-cell phagocytosis. 5F9 synergizes with rituximab to eliminate B-cell non-Hodgkin's lymphoma cells by enhancing macrophage-mediated antibody-dependent cellular phagocytosis. This combination was evaluated clinically.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research